September 17, 2026

Ultragenyx FAYUVI Sanfilippo Type A First-Ever FDA Approval, Novo Rebrand, Dualitas + Roche $1B Bispecific Deal

FDA approves Ultragenyx FAYUVI as first-ever Sanfilippo Type A treatment, Novo Nordisk rebrands to 'Novo', Dualitas-Roche $1B bispecific I&I deal.

6 stories · Covering regulatory, industry

Editor's Note

Thursday brought the year's most consequential rare-pediatric-disease approval: the FDA granted standard full approval to Ultragenyx's FAYUVI (rebisufligene etisparvovec-hopf, previously UX111), a one-time AAV9 gene therapy for pediatric patients with mucopolysaccharidosis type IIIA (Sanfilippo syndrome Type A), the first-ever therapy for a progressive fatal neurodegenerative disorder that had no treatment options before Thursday. Approval landed two days ahead of the September 19 PDUFA action date on a clinical package showing a 23.5-point cognitive-score advantage over natural-history controls. Ultragenyx received a Priority Review Voucher (historically valued $150-350 million on the secondary market) and priced FAYUVI at a $3.95 million per-patient wholesale acquisition cost. RARE shares gained 13% during the day and extended after hours. Elsewhere, the corporate rebrand story of the week continued as Novo Nordisk on Monday September 14 introduced its updated corporate identity — the operating brand now reads simply 'Novo' (legal entity name Novo Nordisk unchanged) — with a new tagline (Lasting health starts now), refreshed Apis-bull logo, and a culture framework called The Novo Way, all pointing to the September 21 Capital Markets Day in London where CEO Mike Doustdar is expected to lay out fresh strategic ambitions after the September 11 Morgan Stanley Underweight downgrade. Dualitas Therapeutics announced a research collaboration and license agreement with Roche potentially worth $1 billion (including $36.5 million upfront) to screen 300,000+ bispecific-antibody combinations for immunology and inflammation indications. NICE issued final draft guidance recommending Daiichi Sankyo / AstraZeneca's Enhertu (trastuzumab deruxtecan, HER2-targeted antibody-drug conjugate) for routine NHS use in HER2-low advanced or metastatic breast cancer after chemotherapy progression. And the FDA is accepting comments through September 28 on revised draft guidance for 17 generic peptide products including semaglutide and tirzepatide.

Regulatory

FDA Grants Standard Full Approval of Ultragenyx FAYUVI (Rebisufligene Etisparvovec-Hopf) as First-Ever Treatment for Pediatric Sanfilippo Syndrome Type A / MPS IIIA; $3.95M WAC Price and Priority Review Voucher Awarded

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced Thursday September 17, 2026 that the FDA granted standard full approval to FAYUVI (rebisufligene etisparvovec-hopf, previously UX111) — a one-time intravenous AAV9-delivered gene therapy carrying a functional copy of the SGSH (N-sulfoglucosamine sulfohydrolase) gene — for the treatment of pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A). MPS IIIA is a progressive, ultimately fatal autosomal-recessive lysosomal storage disorder that causes rapid neurodegeneration in early childhood; before Thursday, no disease-modifying therapy existed. The approval landed two days ahead of the September 19 PDUFA action date, followed the July 2025 complete response letter that had cited chemistry-manufacturing-controls issues plus manufacturing-site observations. The clinical package supporting standard full approval (not accelerated): up to 8 years of follow-up in treated children, sustained cerebrospinal fluid heparan sulfate reduction (the accumulating substrate), and a 23.5-point cognitive-score advantage over natural-history controls. Ultragenyx received a Rare Pediatric Disease Priority Review Voucher — historically valued $150-350 million on the secondary market — alongside the approval, plus U.S. per-patient wholesale acquisition cost set at $3.95 million. RARE shares closed the day up 13% and extended gains after hours. FAYUVI is manufactured domestically at Andelyn Biosciences in Columbus, Ohio and Ultragenyx's own Bedford, Massachusetts facility. Second gene therapy approval for the company.

#ultragenyx #rare #fayuvi #rebisufligene-etisparvovec-hopf #ux111 #aav9-gene-therapy #sanfilippo-syndrome-type-a #mps-iiia #sgsh-gene #first-ever-treatment #standard-full-approval #23-5-point-cognitive-advantage #3-95-million-wac-price #rare-pediatric-disease-prv #crl-resolved #rare-plus-13-percent #non-peptide

Industry

Novo Nordisk Rebrands as 'Novo' With New 'Lasting Health Starts Now' Tagline and 'The Novo Way' Culture Framework Ahead of September 21 London Capital Markets Day

Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) announced Monday September 14, 2026 the rollout of its updated corporate identity: the operating brand is now simply 'Novo' with the tagline 'Lasting health starts now' plus a new culture framework called 'The Novo Way,' anchored by a refreshed version of the historic Apis bull logo. The legal entity name Novo Nordisk A/S is unchanged, and the NYSE ticker (NVO) and Copenhagen (NOVO-B) tickers remain. CEO Mike Doustdar is expected to detail the strategic backing for the rebrand at the September 21 Capital Markets Day in London — the first Novo Capital Markets Day since Doustdar was named CEO and following the Morgan Stanley Underweight downgrade on Friday September 11 (DKK 250 target, semaglutide patent cliff concerns), Barclays trim from DKK 310 to DKK 300, and HSBC target raise to DKK 320 (Hold). The rebrand pairs with an operational push to regain U.S. Wegovy/Ozempic prescription share against Lilly's tirzepatide franchise, plus the September 16 Anthropic Claude Science R&D collaboration, September 7 STEP Young pediatric semaglutide win, and September 4-7 ziltivekimab HERMES + ATHENA heart-failure trial terminations that have narrowed the non-GLP-1 diversification story.

#novo-nordisk #nvo #novo-b #novo-rebrand #lasting-health-starts-now #the-novo-way-culture #apis-bull-logo #mike-doustdar-ceo #capital-markets-day-london-september-21 #morgan-stanley-underweight-context #step-young-context #ziltivekimab-context #anthropic-claude-context #glp-1

Industry

Dualitas Therapeutics Signs Research Collaboration and License Agreement With Roche Worth Up to $1 Billion ($36.5M Upfront) to Screen 300,000+ Bispecific Antibody Combinations for Immunology and Inflammation

Dualitas Therapeutics announced Thursday September 17, 2026 a research collaboration and license agreement with Roche worth up to $1 billion (including $36.5 million upfront plus research, development, and commercial milestone payments and tiered royalties) to discover and develop novel bispecific antibody therapeutics for immunology and inflammation (I&I) indications. Dualitas will apply its DualScreen Bispecific Discovery Engine — a proximity-biology-anchored functional-screening platform — to evaluate more than 300,000 novel bispecific combinations, one of the largest bispecific-screening endeavors publicly announced to date. Roche will assume responsibility for all subsequent preclinical development, regulatory, manufacturing, and commercial activities across the collaboration. The Dualitas platform positions bispecifics as vehicles for synergistic activities unattainable with conventional antibodies. The deal follows Roche's growing focus on I&I as one of its stated therapeutic pillars alongside oncology, neuroscience, and cardiometabolic disease. It also extends Roche's recent deal-making momentum, which included the September 8 Alteogen ALT-B4 subcutaneous-conversion licensing agreement worth up to $3.22 billion.

#dualitas-therapeutics #roche #rhhby #1-billion-deal #36-5-million-upfront #bispecific-antibody-discovery #dualscreen-platform #300000-combinations #proximity-biology #immunology-inflammation #i-and-i-diseases #alteogen-context #non-peptide

Regulatory

NICE Issues Final Draft Guidance Recommending Enhertu (Trastuzumab Deruxtecan) for Routine NHS Use in HER2-Low Advanced or Metastatic Breast Cancer After Chemotherapy Progression

The UK's National Institute for Health and Care Excellence (NICE) issued Thursday September 17, 2026 final draft guidance recommending Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab deruxtecan, HER2-targeted antibody-drug conjugate combining an anti-HER2 antibody with a topoisomerase I inhibitor payload via a cleavable linker) for routine National Health Service use in adults with HER2-low advanced or metastatic breast cancer whose disease has progressed after prior chemotherapy. The NICE recommendation is based on DESTINY-Breast04 Phase 3 data documenting a 6.4-month improvement in median progression-free survival and a 6.6-month improvement in median overall survival versus physician's choice chemotherapy in HER2-low mBC. This is one of the last major geographies to add routine HER2-low mBC coverage for Enhertu, which has been approved by the FDA (August 2022 HER2-low, January 2025 HER2-ultralow) and the EMA. The NICE reversal follows an earlier draft rejection based on cost-effectiveness concerns; the final recommendation reflects updated commercial arrangements with AstraZeneca-Daiichi Sankyo through the NHS.

#nice-uk #national-institute-health-care-excellence #final-draft-guidance #enhertu #trastuzumab-deruxtecan #her2-targeted-adc #her2-low-breast-cancer #routine-nhs-use #daiichi-sankyo #astrazeneca #destiny-breast04 #6-6-month-os-improvement #post-chemotherapy-progression #non-peptide

Regulatory

FDA Revises Draft Guidance for 17 Generic Peptide Products Including Semaglutide and Tirzepatide; Public Comment Period Runs Through September 28, 2026

The U.S. FDA published updated draft guidance for 17 generic peptide products in early September 2026, with the public comment period running through September 28, 2026. The guidance covers testing standards, comparative analytical assessment expectations, and immunogenicity considerations for generic filings of semaglutide, tirzepatide, and 15 other approved peptide products where patents will expire in the coming decade. The 17-peptide update is the most significant FDA generic-peptide policy activity since the 2023 Peptide Guidance Update and lands as the semaglutide patent cliff (2031 loss of exclusivity in major markets) plus tirzepatide's earliest generic entry window (December 2027 for one composition claim, later for others) begin to shape U.S. generic-manufacturer investment decisions. The Indian semaglutide patent expired March 2026, and licensed generics from Biocon, Dr. Reddy's, Sun Pharma, and others followed within weeks; Nomura Research projected the Indian semaglutide generic market at ₹12,000 crore over five years. The FDA guidance is expected to shape U.S. Abbreviated New Drug Application (ANDA) filings post-patent-expiry and represents one of the more consequential regulatory clarifications for peptide biosimilar and generic pathways in years.

#fda-generic-peptide-guidance #17-peptides-revised #semaglutide-generic #tirzepatide-generic #public-comment-september-28 #anda-filings #2031-semaglutide-loss-of-exclusivity #december-2027-tirzepatide-composition #biocon-dr-reddys-generics #sun-pharma-generic #12000-crore-indian-market #peptide-generic-pathway

Industry

BMO Capital Markets Reads Lilly Retatrutide Phase 3 TRIUMPH-2 + TRIUMPH-3 Analyst Note Thursday Positively; Q1 2027 BLA Filing Timeline Confirmed

BMO Capital Markets published a Thursday September 17, 2026 morning analyst note reading Eli Lilly's (NYSE: LLY) TRIUMPH Phase 3 program readouts for retatrutide (once-weekly subcutaneous injectable triple-hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors) as positive for retatrutide's efficacy and benefit-risk profile. TRIUMPH-2 evaluates retatrutide in adults with obesity or overweight plus type 2 diabetes; TRIUMPH-3 evaluates retatrutide in adults with severe obesity plus established cardiovascular disease. TRIUMPH-3 topline reported in July 2026 documented an average 22.6% body weight reduction at 80 weeks at the highest dose. TRIUMPH-1 (the base obesity indication, reported May 2026) documented up to 28.3% mean weight loss at 80 weeks. Lilly guided to a Q1 2027 Biologics License Application (BLA) filing across obesity, obstructive sleep apnea, and knee osteoarthritis pain, deferred from the prior late-2026 timeline. Retatrutide would be the first triple hormone receptor agonist to reach FDA review; its efficacy exceeds tirzepatide (Zepbound/Mounjoro, 20.2% in SURMOUNT-5 vs Wegovy 13.7% at 72 weeks) and semaglutide (Wegovy 13.7% same trial) by clinically relevant margins.

#eli-lilly #lly #retatrutide #triple-hormone-receptor-agonist #gip-glp-1-glucagon #bmo-capital-markets-analyst-note #triumph-2-t2d #triumph-3-cvd #triumph-1-obesity #22-6-percent-triumph-3 #28-3-percent-triumph-1 #q1-2027-bla-filing #obesity-osa-oa #surmount-5-comparator #glp-1